Value proposition

Providing AI software to optimize clinical trials and enhance diagnostic processes to improve patients' lives worldwide

ArtiQ, a spin-off from the Belgian university KU Leuven, is a leading innovative software company dedicated to enhancing the diagnosis and monitoring of patients with respiratory conditions. Moreover, ArtiQ strives to streamline and optimize respiratory clinical trials for pharmaceutical companies. Through the development and provision of cutting-edge AI-first software, ArtiQ empowers traditional respiratory devices and processes.

In April 2024, ArtiQ joined forces with Clario, a leading healthcare research and technology company. This collaboration allows ArtiQ to broaden its reach globally across various clinical trials and sponsors, aiming to extend its impact beyond respiratory care and foster positive outcomes in healthcare worldwide.


Pulmonary function tests, Respiratory problems, Lung diseases, Artificial Intelligence, Digital Health, Diagnostics, and Decision support systems